Journey Strategic Wealth LLC Sells 187 Shares of Eli Lilly and Company (NYSE:LLY)

Journey Strategic Wealth LLC lessened its stake in Eli Lilly and Company (NYSE:LLYFree Report) by 10.4% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 1,611 shares of the company’s stock after selling 187 shares during the quarter. Journey Strategic Wealth LLC’s holdings in Eli Lilly and Company were worth $865,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also bought and sold shares of the company. Thompson Investment Management Inc. acquired a new position in Eli Lilly and Company in the third quarter valued at about $27,000. Retirement Group LLC grew its holdings in shares of Eli Lilly and Company by 159.1% during the second quarter. Retirement Group LLC now owns 57 shares of the company’s stock worth $27,000 after purchasing an additional 35 shares during the last quarter. Legacy Financial Group LLC bought a new stake in shares of Eli Lilly and Company during the third quarter worth about $35,000. Cornerstone Planning Group LLC bought a new stake in shares of Eli Lilly and Company during the second quarter worth about $33,000. Finally, Family CFO Inc bought a new stake in shares of Eli Lilly and Company during the third quarter worth about $40,000. Institutional investors and hedge funds own 81.38% of the company’s stock.

Insider Activity at Eli Lilly and Company

In other news, major shareholder Lilly Endowment Inc sold 1,180 shares of the company’s stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $645.60, for a total value of $761,808.00. Following the completion of the sale, the insider now directly owns 99,542,630 shares of the company’s stock, valued at approximately $64,264,721,928. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Insiders sold a total of 195,055 shares of company stock valued at $125,254,657 in the last quarter. Insiders own 0.13% of the company’s stock.

Analyst Upgrades and Downgrades

A number of research firms recently commented on LLY. Deutsche Bank Aktiengesellschaft began coverage on Eli Lilly and Company in a research note on Thursday, November 9th. They issued a “hold” rating and a $535.00 price objective on the stock. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $630.00 target price on shares of Eli Lilly and Company in a research report on Thursday. Barclays upped their target price on Eli Lilly and Company from $630.00 to $680.00 and gave the stock an “overweight” rating in a research report on Tuesday, January 23rd. JPMorgan Chase & Co. reiterated an “overweight” rating on shares of Eli Lilly and Company in a report on Wednesday, November 8th. Finally, StockNews.com raised Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, November 3rd. One investment analyst has rated the stock with a sell rating, two have issued a hold rating and seventeen have assigned a buy rating to the company’s stock. According to data from MarketBeat, Eli Lilly and Company currently has a consensus rating of “Moderate Buy” and an average target price of $589.90.

Check Out Our Latest Stock Report on Eli Lilly and Company

Eli Lilly and Company Stock Up 5.9 %

LLY stock traded up $39.08 during trading on Monday, reaching $706.73. The stock had a trading volume of 2,787,022 shares, compared to its average volume of 2,923,007. The firm has a fifty day moving average price of $606.79 and a 200 day moving average price of $572.66. The company has a market capitalization of $670.91 billion, a P/E ratio of 128.88, a PEG ratio of 2.16 and a beta of 0.32. Eli Lilly and Company has a 1-year low of $309.20 and a 1-year high of $711.88. The company has a current ratio of 1.05, a quick ratio of 0.82 and a debt-to-equity ratio of 1.59.

Eli Lilly and Company (NYSE:LLYGet Free Report) last announced its quarterly earnings data on Thursday, November 2nd. The company reported $0.10 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.08) by $0.18. Eli Lilly and Company had a net margin of 15.55% and a return on equity of 48.12%. The business had revenue of $9.50 billion during the quarter, compared to the consensus estimate of $8.88 billion. On average, equities analysts anticipate that Eli Lilly and Company will post 6.34 earnings per share for the current year.

Eli Lilly and Company Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Monday, March 4th. Investors of record on Thursday, February 15th will be given a dividend of $1.30 per share. This represents a $5.20 dividend on an annualized basis and a dividend yield of 0.74%. The ex-dividend date of this dividend is Wednesday, February 14th. This is an increase from Eli Lilly and Company’s previous quarterly dividend of $1.13. Eli Lilly and Company’s dividend payout ratio is currently 81.88%.

Eli Lilly and Company Company Profile

(Free Report)

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. It offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; and Jardiance, Trajenta, and Trulicity for type 2 diabetes.

Further Reading

Institutional Ownership by Quarter for Eli Lilly and Company (NYSE:LLY)

Receive News & Ratings for Eli Lilly and Company Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eli Lilly and Company and related companies with MarketBeat.com's FREE daily email newsletter.